Onkológia S1/2026
Systemic therapy of a patient with de novo metastatic prostate carcinomainitially
Introduction: Novel systemic therapy options for metastatic prostate carcinoma, including antiandrogens, have been able to significantly improve patient survival.
Case report: This case report presents the experience with treatment of a 68-year-old male with de novo metastatic prostate cancer, who was treated with androgen deprivation therapy and docetaxel for castration-sensitive disease in the context of historical data. Following progression to the castration-resistant stage, he was treated with an androgen receptor pathway inhibitor in the first line with progression-free survival of 41 months. During treatment with enzalutamide, no serious adverse events were recorded, only mild fatigue and hypertension). In the subsequent lines, he received radioligand therapy (177 lutetium - PSMA), following progression the patient continues in the cabazitaxel therapy.
Conclusion: Enzalutamide in the first line of castration-resistant prostate carcinoma represents a safe and effective treatment strategy.
Keywords: prostate carcinoma, metastatic disease, enzalutamide, radioligands, taxanes
